My Top Dividend Growth Stock to Buy in July and Hold Forever

BDX reads as a quality-compounder rather than a re-rating story. In this tape, the market is likely to pay for the combination of recurring consumables and cash return only if management can keep EPS growth ahead of pricing pressure; otherwise the stock behaves like a duration asset with downside limited by yield support but upside capped by low organic growth. The main second-order winner is not BDX alone, but defensive medtech relative to higher-beta healthcare names: capital can rotate toward companies with visible cash generation while away from R&D-heavy platforms that need faster reinvestment to justify their multiples.

The near-term catalyst is earnings/guidance, not the dividend commentary. Watch whether buybacks are merely offsetting dilution or actually shrinking share count enough to lift per-share metrics; if not, the “total yield” narrative loses power quickly. The key falsifier is a flat-to-down forward EPS guide or any evidence that hospital purchasing pressure is forcing price concessions—consumables are recurring, but they are not immune to GPO-driven compression.

Contrarian take: the consensus may be underestimating how little rerating power a cheap multiple has when growth is mature. A move from 12x to the historical average can happen, but without accelerating volumes or margin leverage, that rerating is likely measured in turns, not a structural break. Over 6-18 months, BDX looks more like a defensive ballast than a source of alpha unless healthcare risk appetite deteriorates materially.